risperidone / Generic mfg. |
NCT01363349: Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia |
|
|
| Terminated | 2b | 269 | Europe, RoW | CYP-1020, BL-1020, Risperidone | BioLineRx, Ltd. | Schizophrenia, Cognitive Effect on Schizophrenic Patients | 03/13 | 04/13 | | |
|
NCT00921804: Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients |
|
|
| Completed | 2a | 296 | US | AZD 8529, Risperidone, Risperdal, Placebo to match AZD8529, Placebo to match risperidone | AstraZeneca | Schizophrenia | 05/10 | 05/10 | | |
| Completed | 2 | 231 | US | talnetant, risperidone | GlaxoSmithKline | Schizophrenia | 04/03 | 04/03 | | |
NCT00639483: Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia |
|
|
| Completed | 2 | 270 | Europe, RoW | Celecoxib, Placebo | Pfizer | Schizophrenia | | 01/04 | | |
NCT00300963: Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients |
|
|
| Completed | 2 | 275 | US | Talnetant | GlaxoSmithKline | Schizophrenia | 10/05 | 10/05 | | |
NCT00103727: Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia |
|
|
| Completed | 2 | 282 | US | Talnetant, placebo, risperidone | GlaxoSmithKline | Schizophrenia | 10/05 | 10/05 | | |
NCT00361166: Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone |
|
|
| Completed | 2 | 400 | US, RoW | ACP-103 | ACADIA Pharmaceuticals Inc. | Schizophrenia | | 03/07 | | |
| Completed | 2 | 338 | US, Europe, RoW | SB-773812, Olanzapine | GlaxoSmithKline | Schizophrenia | | 08/07 | | |
NCT00563706: Study Evaluating Vabicaserin in Subjects With Schizophrenia |
|
|
| Completed | 2 | 199 | US, Canada | vabicaserin, risperidone, placebo | Pfizer | Schizophrenia | 06/08 | 06/08 | | |
NCT00722176: Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 |
|
|
| Completed | 2 | 220 | US | BL-1020, BL-1020 10-30 mg, BL-1020 High Dose, risperidone | BioLineRx, Ltd. | Schizophrenia | 07/09 | 12/09 | | |
NCT00567710: A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study |
|
|
| Completed | 2 | 360 | US | BL - 1020, Placebo, Risperidone | BioLineRx, Ltd. | Schizophrenia | 07/09 | 09/09 | | |
|
|
NCT00768612: Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia |
|
|
| Withdrawn | 2 | 0 | Japan | SCA-136 50mg/day, SCA-136 150 mg/day, SCA-136 300mg/day, Risperidone 4mg/day | Wyeth is now a wholly owned subsidiary of Pfizer | Schizophrenia | 07/09 | 07/09 | | |
CONNECT, NCT00439634: Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia |
|
|
| Terminated | 2 | 873 | US, Canada | AVE1625, Drinabant, placebo | Sanofi | Schizophrenia | 09/09 | 09/09 | | |
| Completed | 2 | 124 | Europe, RoW | Lu AE58054, Placebo | H. Lundbeck A/S | Schizophrenia, Cognition | 01/10 | 02/10 | | |
STAR-1, NCT00509067: Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia |
|
|
| Completed | 2 | 43 | US | Galantamine, Razadyne, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole | Georgetown University, National Institute of Mental Health (NIMH), Washington D.C. Veterans Affairs Medical Center | Schizophrenia | 03/11 | 03/11 | | |
NCT01175135 / 2010-020764-38: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia |
|
|
| Completed | 2 | 259 | US, Europe, RoW | PF-02545920, Placebo, Risperidone, Risperdal | Pfizer | Schizophrenia | 08/11 | 08/11 | | |
| Completed | 2 | 880 | US, RoW | Risperidone, Placebo, LY2140023 | Eli Lilly and Company | Schizophrenia | 05/12 | 05/12 | | |
|
| Completed | 2 | 7 | Europe | Pipamperone, Risperdal, Invega and Xeplion, Placebo | PharmaNeuroBoost N.V. | Chronic Schizophrenia, Schizoaffective Disorder | 11/12 | 12/12 | | |
NCT01499563: Study of a Novel Antipsychotic ITI-007 in Schizophrenia |
|
|
| Completed | 2 | 335 | US | ITI-007, Placebo, Risperidone | Intra-Cellular Therapies, Inc. | Schizophrenia | 08/13 | 11/13 | | |
|
|
|
NCT01623713: Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia |
|
|
| Completed | 2 | 260 | RoW | iloperidone, Risperidone | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Schizophrenia, Iloperidone, Efficacy | 10/13 | 11/13 | | |
| Completed | 2 | 12 | US | Risperidone + Desipramine, Norpramin | Dartmouth-Hitchcock Medical Center, University of South Carolina, University of Massachusetts, Worcester, Michigan State University | Schizophrenia, Alcoholism, Dual Diagnosis | 08/14 | 09/14 | | |
NCT00653406: A Pharmacokinetic and Safety Study of Risperidone Long Acting Injectable in Schizophrenic Patients |
|
|
| Completed | 1/2 | 29 | Japan | Risperidone long acting injectable | Janssen Pharmaceutical K.K. | Schizophrenia | | 10/03 | | |